These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22318829)

  • 1. Cytomegalovirus infection according to cell source after hematopoietic cell transplantation in pediatric patients.
    Yi ES; Kim YJ
    Yonsei Med J; 2012 Mar; 53(2):393-400. PubMed ID: 22318829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: no evidence of increased incidence in patients receiving unrelated donor grafts.
    Foot AB; Pamphilon D; Caul EO; Roome AP; Hunt LP; Cornish JM; Oakhill A
    Br J Haematol; 1998 Aug; 102(3):671-7. PubMed ID: 9722292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors.
    Yoon HS; Lee JH; Choi ES; Seo JJ; Moon HN; Kim MN; Im HJ
    Pediatr Transplant; 2009 Nov; 13(7):898-905. PubMed ID: 19032414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus infections in unrelated cord blood transplantation in pediatric patients: incidence, risk factors, and outcomes.
    Al-Hajjar S; Al Seraihi A; Al Muhsen S; Ayas M; Al Jumaah S; Al Jefri A; Shoukri M; El Solh H
    Hematol Oncol Stem Cell Ther; 2011; 4(2):67-72. PubMed ID: 21727767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Surveillance of cytomegalovirus for antiviral efficacy and risk factors in allogeneic hematopoietic stem cell transplantation].
    Jia JS; Liu DP; Huang XJ; Wu T; Liu DH; Zhang YC; Su H; Wang JB; Zhou JR; Liu Q; Ying MY; Sun RJ; Duan X; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):749-54. PubMed ID: 16928314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution.
    Melendez-Munoz R; Marchalik R; Jerussi T; Dimitrova D; Nussenblatt V; Beri A; Rai K; Wilder JS; Barrett AJ; Battiwalla M; Childs RW; Fitzhugh CD; Fowler DH; Fry TJ; Gress RE; Hsieh MM; Ito S; Kang EM; Pavletic SZ; Shah NN; Tisdale JF; Gea-Banacloche J; Kanakry CG; Kanakry JA
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):577-586. PubMed ID: 30342913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
    Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
    Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
    Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center.
    Rowe RG; Guo D; Lee M; Margossian S; London WB; Lehmann L
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1275-1283. PubMed ID: 27090959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
    Ju HY; Kang HJ; Hong CR; Lee JW; Kim H; Park KD; Shin HY; Park JD; Choi EH; Lee HJ; Ahn HS
    Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources.
    Walker CM; van Burik JA; De For TE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1106-15. PubMed ID: 17697973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy.
    Behrendt CE; Rosenthal J; Bolotin E; Nakamura R; Zaia J; Forman SJ
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):54-60. PubMed ID: 19135943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.
    Nichols WG; Corey L; Gooley T; Drew WL; Miner R; Huang M; Davis C; Boeckh M
    Blood; 2001 Feb; 97(4):867-74. PubMed ID: 11159510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
    Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
    Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed vs full donor engraftment early after hematopoietic cell transplant: Impact on incidence and control of cytomegalovirus infection.
    Green JS; Shanley RM; Brunstein CG; Young JH; Verneris MR
    Transpl Infect Dis; 2019 Jun; 21(3):e13070. PubMed ID: 30864271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
    Nakamae H; Kirby KA; Sandmaier BM; Norasetthada L; Maloney DG; Maris MB; Davis C; Corey L; Storb R; Boeckh M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):694-703. PubMed ID: 19450754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.